TB Alliance
By
FIND,
TB Alliance,
IAVI
Published: April 4, 2022, 4:59 p.m.·
Tags:
Global TB response
On 11 April 2022, FIND, the global alliance for diagnostics, TB Alliance and the International AIDS Vaccine Initiative (IAVI) will host a webinar bringing together a panel of experts to review both new and experimental tools that have the potential to end TB for good, and what is needed to bring them to scale and achieve public health impact.
Read More →
By
TB Alliance
Published: Jan. 27, 2022, 9:53 p.m.·
Tags:
Research and development
Statement on 2021 G-FINDER Report
Read More →
By
TB Alliance
Published: Jan. 20, 2022, 9:25 p.m.·
Tags:
Treatment,
Scientific research
NEW YORK, NY (20 January 2022) — Today, TB Alliance announced that it has received funding from the United States Agency for International Development (USAID) to jumpstart the search for new tuberculosis (TB) treatments, optimize current treatments so that they can treat children as well as adults, and strengthen health systems in high-TB-burden countries so that all people with TB disease can get treated and quickly return to full health. The funding of up to US$30 million will be administered over a period of 5 years.
Read More →
By
TB Alliance
Published: Sept. 6, 2021, 12:24 a.m.·
Tags:
Drug-resistant TB,
Treatment,
Access
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug.
Read More →
By
TB Alliance
Published: Aug. 19, 2021, 1:24 a.m.·
Tags:
Drug-resistant TB,
Treatment
On 12 August 2021, TB Alliance hosted a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
Read More →
By
TB Alliance
Published: Aug. 5, 2021, 11:46 p.m.·
Tags:
Drug-resistant TB,
Treatment
On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
Read More →
By
TB Alliance
Published: Aug. 5, 2021, 12:15 a.m.·
Tags:
Drug-resistant TB,
Treatment,
Access
TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
Read More →
By
TB Alliance,
KNCV Tuberculosis Foundation
Published: Aug. 5, 2021, 12:02 a.m.·
Tags:
Drug-resistant TB,
Treatment
TB Alliance and KNCV Tuberculosis Foundation published a study in BMC Public Health, focused on collecting stakeholder views (in Nigeria, Indonesia, and Kyrgyzstan) regarding the acceptability, feasibility, and likelihood of stakeholders implementing the BPaL regimen. BPal is a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.
Read More →
By
TB Alliance
Published: July 15, 2021, 9:11 a.m.·
Tags:
Scientific research,
Research and development,
Medicines
The partnership will accelerate the development of new TB drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium.
Read More →
By
TB Alliance
Published: July 15, 2021, 9 a.m.·
Tags:
Drug-resistant TB,
Treatment
The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
Read More →
Page 2 of 11 · Total posts: 10
←First
1
2
3
Last→